Urovant Sciences Announces FDA Acceptance of New Drug Application for Vibegron for the Treatment of…
Urovant Sciences announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for once-daily 75 mg vibegron for the…
Read More...
Read More...
